Cognitive deficit is a core symptom of schizophrenia related to poorer functional outcome. Prior studies indicated that abnormalities in the hippocampus-prefrontal circuit and glutamate/GABA imbalances may lead to cognitive deficits. Based on the current background and our previous studies, it has been proved that TUS can modulate neural excitability and plasticity in the hippocampus. In this double-blind, randomized study, the efficacy of different treatment options and mechanisms of TUS on cognitive deficits will be investigated.
Meet the DSM-5 diagnostic criteria for schizophrenia ;
Age18-50, right-handed, Han nationality;
Presence of cognitive deficit: defined as d' value <0.5 in associative memory test;
Be in a stable condition, received second-generation antipsychotics for at least 4 weeks or more;
Current or past neurological illness, severe physical diseases, substance abuse or alcohol dependence, mental retardation, pregnancy or lactation;
Uncooperative or risky patients with high excitement, stupor, disorder of words and deeds, negative suicide, etc.;
History of MECT or other physical therapy within 6 months;
History of epilepsy, or epileptic waves on the baseline EEG;